LivaNova (NASDAQ:LIVN – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a research report on Wednesday. Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. According to MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $83.50. LivaNova Company Profile(Get Free Report)LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets.